Amyloidosis

4:07
The potential of anti-amyloid antibodies to treat amyloidosis
Suzanne Lentzsch et al.
2:26
Biomarkers of amyloidosis
Giampaolo Merlini
1:44
New antibody treatments for AL amyloidosis
Giampaolo Merlini
3:02
Unmet needs in amyloidosis
Giampaolo Merlini
1:29
Treatment outcomes of elderly patients with AL Amyloidosis
Giampaolo Merlini
3:17
Exciting improvements in amyloidosis management and treatment
Ashutosh Wechalekar
3:38
Game-changing drugs for amyloidosis treatment
Ashutosh Wechalekar
2:11
An unmet need: reducing early death in amyloidosis
Ashutosh Wechalekar
0:42
Upcoming amyloidosis clinical trial data to look forward to at ASH 2017
Ashutosh Wechalekar
4:12
Major breakthroughs in AL amyloidosis treatment from ASH 2017
Laurent Garderet
0:53
NEOD001 in amyloidosis
Morie Gertz
2:55
Amyloidosis: patient fitness determines therapeutic strategies
Giampaolo Merlini
2:32
New therapies shaping the future of amyloidosis
Giampaolo Merlini
2:22
NEOD001: changing the treatment of amyloidosis
Morie Gertz
3:06
MRD in myeloma and proteasome inhibition in amyloidosis
Rafael Fonseca
5:39
Renal complications in multiple myeloma – characteristics and treatment
Nelson Leung
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals